Novavax Reports Significant Revenue Decline in Q2 2026, Net Loss of $53.4 Million

Novavax, Inc. reported a significant decline in financial performance for the second quarter of 2026, with total revenue of $56.7 million, down from $239.2 million in the same period of 2025. This decrease of $182.5 million was primarily attributed to a sharp decline in licensing, royalties, and other revenue, which fell to $37.8 million from $228.5 million year-over-year. The company's product sales, however, increased to $18.9 million from $10.7 million, driven by supply sales of its COVID-19 vaccine and related materials, as the company transitioned commercial sales responsibilities to its partner, Sanofi.

For the first half of 2026, Novavax reported total revenue of $196.2 million, a decrease of $709.7 million compared to $905.9 million in the first half of 2025. The decline was largely due to the absence of nonrecurring revenue from the termination of advance purchase agreements (APAs) with Canada and New Zealand, which had contributed significantly to the previous year's figures. Product sales for the six months ended June 30, 2026, were $61.1 million, down from $632.4 million, reflecting a substantial drop in Nuvaxovid™ sales.

Total expenses for the second quarter of 2026 were $111.6 million, a reduction from $138.2 million in the prior year, primarily due to cost containment measures. Research and development expenses decreased to $70.7 million from $79.2 million, while selling, general, and administrative expenses fell to $26.7 million from $43.6 million. Despite these reductions, Novavax reported a net loss of $53.4 million, or $0.32 per share, compared to a net income of $106.5 million, or $0.66 per share, in the same quarter of 2025.

Operationally, Novavax continues to focus on its strategic partnerships, particularly with Sanofi, which is expected to enhance its market presence and revenue potential. The company is also advancing its restructuring plan to optimize its operations and reduce costs. As of June 30, 2026, Novavax had cash, cash equivalents, and marketable securities totaling $723.9 million, down from $750.5 million at the end of 2025. The company anticipates that its current financial resources will be sufficient to fund operations for at least the next 12 months.

Looking ahead, Novavax remains committed to its growth strategy, which includes maximizing the impact of its technology platform and pursuing new partnerships. The company is also focused on advancing its pipeline of vaccine candidates, including a potential combination vaccine for COVID-19 and influenza, and plans to continue its research and development efforts in various therapeutic areas.